Genentech reinvested approximately 21 percent of its operating revenues on a GAAP basis into research and development in 2008 — significantly more than the pharmaceutical industry average. To balance resource use with the strongest likelihood of success, Genentech continuously evaluates its pipeline products in order to determine which are the most promising projects to move through the many phases of clinical testing.
Genentech's development pipeline continues to grow, now numbering more than 100 projects in the following therapeutic focus areas: oncology, immunology, disorders of tissue growth and repair, and neuroscience. The pipeline includes both breakthrough innovations and potential new indications for existing, well-understood products that may fight more than one disease or more than one form of a disease.
Please refer to the product/project links provided below for detailed information regarding the development status of a project.
| Awaiting FDA Action | |
| Avastin® |
First-line metastatic renal cell carcinoma Previously treated glioblastoma |
| Rituxan®/Immunology |
Rheumatoid arthritis DMARD-inadequate responders |
| Tarceva® |
First-line maintenance therapy for advanced non-small cell lung cancer |
| Xolair® |
Pediatric asthma |
| FDA Submission Preparation | |
| Avastin |
First-line HER2-negative metastatic breast cancer (RIBBON-1 and AVADO data) |
| Rituxan Hematology/Oncology |
Previously untreated chronic lymphocytic leukemia Relapsed chronic lymphocytic leukemia |
| Rituxan/Immunology |
Rheumatoid arthritis (radiographic data) |
| Phase III | |
| Avastin |
Adjuvant colon cancer Adjuvant HER2-negative breast cancer Adjuvant HER2-positive breast cancer Adjuvant non-small cell lung cancer Diffuse large B-cell lymphoma First-line advanced gastric cancer First-line HER2-negative metastatic breast cancer First-line HER2-positive metastatic breast cancer First-line metastatic ovarian cancer Gastrointestinal stromal tumors High risk carcinoid Hormone refractory prostate cancer Newly diagnosed glioblastoma multiforme1 Relapsed platinum-sensitive ovarian cancer Second-line HER2-negative metastatic breast cancer Second-line Metastatic Colorectal Cancer |
| Avastin +/- Tarceva |
First-line metastatic non-squamous, non-small cell lung cancer |
| GA101 |
Indolent non-Hodgkin's lymphoma |
| Herceptin® |
Adjuvant HER2-positive breast cancer (HERA 2-year treatment) |
| Lucentis® |
Diabetic macular edema Retinal vein occlusion |
| Ocrelizumab (2nd Generation Anti-CD20) | Lupus nephritis Rheumatoid arthritis |
| Pertuzumab |
First-line HER2-positive metastatic breast cancer Platinum-resistant ovarian cancer1 |
| Rituxan Hematology/Oncology |
Follicular non-Hodgkin's lymphoma |
| Rituxan Immunology |
ANCA-associated vasculitis |
| Tarceva |
Adjuvant non-small cell lung cancer |
| TNKase® |
Central venous catheter clearance Hemodialysis catheter clearance |
| Trastuzumab-DM1 |
Second-line HER2-positive metastatic breast cancer |
| Xolair |
Asthma Liquid formulation |
| Phase II | |
| ABT-869 |
Advanced renal cell carcinoma Advanced or metastatic hepatocellular carcinoma First-line metastatic breast cancer Metastatic non-small cell lung cancer Second-line metastatic colorectal cancer |
| Anti-IL13 | Asthma |
| Apomab |
Indolent relapsed non-Hodgkin's lymphoma First-line metastatic non-small cell lung cancer |
| Avastin |
Extensive small cell lung cancer Non-squamous, non-small cell lung cancer with previously treated CNS metastases Relapsed multiple myeloma |
| Dacetuzumab (Anti-CD40) | Second-line diffuse large B-cell lymphoma |
| Dulanermin (rhApo2L/TRAIL) |
Indolent relapsed non-Hodgkin's lymphoma First-line metastatic non-small cell lung cancer |
| GA101 |
Relapsed or refractory hematologic malignancies Indolent non-Hodgkin's lymphoma |
| Hedgehog Pathway Inhibitor (GDC-0449) |
Advanced basal cell carcinoma First-line metastatic colorectal cancer Ovarian cancer maintenance therapy |
| MetMAb |
Second- and third-line metastatic non-small cell lung cancer |
| Ocrelizumab (2nd Generation Anti-CD20) |
Relapsing remitting multiple sclerosis |
| Pertuzumab |
Second-line metastatic non-small cell lung cancer |
| rhuMAb IFN alpha | Systemic lupus erythematosus1 |
| Trastuzumab-DM1 |
First-line HER2-positive metastatic breast cancer Second-line Third-line HER2-positive metastatic breast cancer |
| Xolair |
Chronic idiopathic urticaria |
| Phase I | |
| ABT-263 |
Chronic lymphocytic leukemia Lymphoid malignancies Small cell lung cancer |
| Anti-Abeta |
Alzheimer's Disease |
| Anti-CD4 |
Rheumatoid arthritis |
| Anti-EGFL7 |
Cancer1 |
| Anti-NRP1 |
Cancer |
| Anti-oxLDL | Secondary prevention of cardiovascular events |
| Apomab |
Colorectal cancer |
| Dacetuzumab (Anti-CD40) |
Diffuse large B-cell lymphoma Multiple myeloma Non-Hodgkin's lymphoma |
| Dulanermin (rhApo2L/TRAIL) |
Colorectal cancer |
| huMAb OX40L | Asthma |
| IAP Antagonist | Cancer |
| MEK Inhibitor | Cancer |
| New Molecular Entity | Autoimmune disease |
| New Molecular Entity | Cancer |
| New Molecular Entity (ADC) | Cancer |
| PI3 Kinase Inhibitor | Cancer |
| rhuMAb Beta7 | Ulcerative colitis |
| Trastuzumab-DM1 + Pertuzumab | HER2-positive metastatic breast cancer1 |
Information updated April 2009
ADC = Antibody Drug Conjugate; ANCA = Anti-neutrophilic Cytoplasmic Antibodies; CNS = Central Nervous System; DMARD = Disease-modifying Anti-rheumatic Drugs; FDA = U.S. Food and Drug Administration.